The thrombolysis in myocardial infarction (TIMI) study group experience


Cite item

Full Text

Abstract

The article presents the history of development of various methods of reperfusion therapy in myocardial infarction. The method of intracoronary thrombolysis was developed and used in Russia in 1976. In 1984 the TIMI Study Group initiated large-scale long-term trial of thrombolytic therapy in myocardial infarction and unstable angina pectoris. Some basic results of the study are outlined.

About the authors

E Braunval'd

E Braunwald

References

  1. Chazov E. I., Mateeva L. S., Mazaev A. V. Intracoronary administration of fibrinolysin in acute myocardial infarction. Ter. Arkh. 1976; 48(4): 8-19.
  2. Tennant E., Wiggers C. J. The effect of coronary occlusion on myocardial contraction. Am. J. Physiol. 1935; 112: 351-361.
  3. Blumgart H. L., Gilligan R., Schlesinger M. J. Experimental studies on the effect of temporary occlusion of coronary arteries. II. The production of myocardial infarction. Am. Heart J. 1941; 22: 374-389.
  4. Braunwald E., Covell J. W., Maroko P. R., Ross J. Jr. Effect of drugs and of counterpulsation on myocardial oxygen consumption. Circulation 1969; 40(suppl. IV): 220-228.
  5. Maroko P. R., Kjekshus J. K., Sobel B. E. et al. Factors influencing infarct size following experimental coronary artery occlusion. Circulation 1971; 43; 67-82.
  6. Maroko P. R., Braunwald E. Modification of myocardial infarction size after coronary occlusion. Ann. Intern. Med. 1973: 79: 720-733.
  7. The TIMI Study Group. Braunwald E. (Chairman). The thrombolysis in myocardial infarction (TIMI) trial. N. Engl. J. Med. 1985; 312: 932-936.
  8. The TIMI Study Group. Braunwald E. (Chairman): Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N. Engl. J. Med. 1989; 320: 618-627.
  9. Roberts R., Rogers W. J., Mueller H. S. Braunwald E for the TIMI Investigators: Immediate versus deferred-blockade following thrombolytic therapy in patients with acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 199l; 83: 422-437.
  10. Antman E. M., Morrow D. A., McCabe C. H. Braunwald E. for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 2006; 354: 1477-1488.
  11. Sabatine M. S., Cannon C. P., Gibson C. M. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 2005; 352: 1179-1189.
  12. Cibson C. M., Kirtane A. J., Murphy S. A. et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am. Heart J. 2006; 152: 668-675.
  13. Morrow D. A., Antman E. M., Sayah A. Braunwald E. on behalf of the Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 investigators. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation MI: Results of the Early Retevase (ER)-TIMI 19 trial. J. Am. Coll. Cardiol. 2002; 40: 71-77.
  14. The TIMI III B Investigators. Braunwald E. (Chairman): Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-q-wave myocardial infarction. Results of the TIMI III B Trial. Circulation 1994; 89: 1545-1556.
  15. Cannon C. P., Weintraub W. S., Demopoulos L. A. et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med. 2001; 344: 1879-1887.
  16. Antman E. M., McCabe C. H., Gurfinkel E. P., Braunwald E. for the TIMI 11B Investigators: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial. Circulation 1999; 100: 1593-1601.
  17. Wiviott S. D., Braunwald E., McCabe C. H. for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2007; 357: 2001-20l5.
  18. Wiviott S. D., Braunwald E., McCabe C. H. for the TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting n the TRITON-TIMI 38 trial: a subanalysis of a randomized trial. Lancet 2008; 371: 1353-1363.
  19. Wiviott S. D., Braunwald E., Angiolillo D. J. for the TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
  20. Wiviott S. D., Trenk D., Frelinger A. L. et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. Circulation 2007; 116: 2923-2932.
  21. Morrow D. A., Scirica B. M., Karwatowska-Prokopczuk E. et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. J. A. M. A. 2007; 297: 1775-1783.
  22. Antman E. M., Cohen M., Bernink P. J. L. M. et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. J. A. M. A. 2000; 284: 835-842.
  23. Morrow D. A., Antman E. M., Charlesworth A. et al. TIMI risk score for ST-elevation myocardial infarction. A convenient, bedside, clinical score for risk assessment at presentation. An intravenous nPA for Treatment of infracting Myocardium Early II Trial substudy. Circulation 2000; 102: 2031-2037.
  24. Morrow D. A., Antman E. M., Parsons L. et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. J. A. M. A. 2001; 286: 1356-1359.
  25. Morrow D. A., Antman E. M., Giugliano R. P. et al. A simple risk index for rapid initial triage of patients with ST elevation myocardial infarction: An In TIME II Substudy. Lancet 2001; 358: 1571-1575.
  26. Gibson C. M., Murphy S. A., Rizzo M. J. et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999; 99: 1945-1950.
  27. Gibson C. M., Cannon C. P., Murphy S. A. et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-130.
  28. Antman E. M., Tanasijevic M. J., Thompson B. et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N. Engl. J. Med. 1996; 335: 1342-1349.
  29. Morrow D. A., Cannon C. P., Rifai N., Braunwald E. for the TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction. Results from a randomized trial. J. A. M. A. 2001; 286: 2405-2412.
  30. de Lemos J. A., Morrow D. A., Bentey J. H. et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 2001; 345: 1014-1021.
  31. Morrow D. A., de Lemos J. A., Blazing M. A., Braunwald E. for the A to Z investigators. Prognostic value of serial B-type natriuretic peptide during follow-up of patients with unstable coronary artery disease. J. A. M. A. 2005; 294: 2866-2871.
  32. Sabatine M. S., Morrow D. A., de Lemos J. A. et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-1763.
  33. Cannon C. P., McCabe C. H., Wilcox R. G. et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-156.
  34. Cannon C. P., Braunwald E., McCabe C. H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350: 1495-1504.
  35. Wiviott S. D., Cannon C. P., Morrow D. A. et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy. J. Am. Coll. Cardiol. 2005; 46: 1411-1416.
  36. Cannon C. P., Giugliano R. P., Blazing M. A., Braunwald E., Califf R. M. for the IMPROVE IT investigators. Design and rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J. 2008; 156: 826-832.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies